Your fact-checks will appear here
Biotech company
For the 2025–2026 U.S. influenza season, federal guidance and product labeling show a clear shift to single‑dose, thimerosal‑free presentations: ACIP and CDC recommend that vaccines for children, preg...
For the 2025–26 U.S. season, most manufacturers are supplying single‑dose, thimerosal‑free prefilled syringes — specifically GSK’s Fluarix and Flulaval, Seqirus’s Afluria and Fluad, and CSL Seqirus’s ...
For the 2025–26 U.S. influenza season, public health authorities and product labels show that most marketed flu vaccines were available as thimerosal-free single‑dose presentations (pre‑filled syringe...
Recombinant and cell‑culture influenza vaccines are manufactured without eggs and therefore avoid egg‑adapted mutations that can alter the vaccine virus’s hemagglutinin antigen; immunologic and observ...
Egg‑based and cell‑based used in 2024–25 have broadly similar safety records with predominantly mild, short‑lived local and systemic reactions, while cell‑based products avoid egg proteins and the egg...
The 2025–2026 U.S. influenza season features a clear policy tilt: public-health advisers and CDC/ACIP recommend using single‑dose formulations that are free of thimerosal for children, pregnant people...